Nuvation Bio Announces FDA Clearance of Investigational New DrugNUVB: Nuvation Bio Inc.
2021-12-13 07:00:00
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Prostate Cancer
−0.38USD
−104.199MUSD
143.735M
About Nuvation Bio Inc.
Sector
Industry
CEO
David T. Hung
Website
Headquarters
New York
Employees (FY)
53
Founded
2018
ISIN
US67080N1019
Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
